Use of Nonsteroidal Anti-Inflammatory Drugs for Symptomatic Treatment of Episodic Headache

Pain Practice ◽  
2016 ◽  
Vol 17 (3) ◽  
pp. 392-401 ◽  
Author(s):  
Giannapia Affaitati ◽  
Paolo Martelletti ◽  
Mariangela Lopopolo ◽  
Claudio Tana ◽  
Francesca Massimini ◽  
...  
Keyword(s):  
Symptomatic Treatment ◽  
Episodic Headache ◽  
Inflammatory Drugs ◽  
Anti Inflammatory

scholarly journals NAPROXEN INDUCED ERYTHEMA MULTIFORME-A RARE CASE REPORT

2017 ◽  
Vol 9 (3) ◽  
pp. 294 ◽  
Author(s):  
Sai Keerthana P. C. ◽  
Anila K. N. ◽  
Reshma Reji
Keyword(s):  
Erythema Multiforme ◽  
Lupus Erythematosus ◽  
Rare Case ◽  
Symptomatic Treatment ◽  
Girl Child ◽  
Rare Case Report ◽  
History Of ◽  
Inflammatory Drugs ◽  
Anti Inflammatory ◽  
Custodial Parents

Erythema multiforme (EM) is a hypersensitivity reaction characterized by varying degrees of blisters and ulcerations. We report a case of 4 y old girl child born for Non-custodial parents who has a history of seizures and a known case of carbamazepine-induced SLE (Systemic Lupus Erythematosus) when treated with anti-inflammatory drugs developed EM. The offending drug was identified and withdrawn. Steroid was given as a part of symptomatic treatment. Non-steroidal anti-inflammatory drugs (NSAIDs) are one of the most commonly prescribed groups of drugs for a variety of indications. The patient gradually improved and got discharged.

ANTI-INFLAMMATORY THERAPY OF THROAT DISEASES

2019 ◽  
Vol 25 (3) ◽  
pp. 53-59
Author(s):  
O.M. Kolesnikova ◽  
◽  
S.A. Karpishchenko ◽  
Y.V. Legkova ◽  
◽  
...  
Keyword(s):  
Quality Of Life ◽  
Respiratory Tract ◽  
Antibiotic Therapy ◽  
Symptomatic Treatment ◽  
Diagnostic Methods ◽  
Active Life ◽  
Systemic Antibiotic Therapy ◽  
Inflammatory Drugs ◽  
Anti Inflammatory

Sore throat is one of the most common complaints faced by doctors of various specialties. This symptom accompanies many diseases of the pharynx and larynx, and may be a manifestation of certain diseases that are not associated with the respiratory tract. When choosing therapy, it is necessary by doctors to rationally use the criteria for the appointment of systemic antibiotic therapy. However, local anti-inflammatory therapy as a symptomatic treatment should be selected before accurate confirmation of the etiology of the disease. This provides patients with a quick return to an active life and an improvement in the quality of life in general. The article discusses the etiology and pathogenesis of pain in diseases of the pharynx, modern diagnostic methods and optimal tactics for treating patients. As a symptomatic treatment, to reduce inflammation in the pharynx, the drug Vertum LOR, which belongs to the group of non-steroidal anti-inflammatory drugs of local action, may contain benzidamine as an active substance.

scholarly journals Biological Basis for the Use of Botanicals in Osteoarthritis and Rheumatoid Arthritis: A Review

2005 ◽  
Vol 2 (3) ◽  
pp. 301-308 ◽  
Author(s):  
Salahuddin Ahmed ◽  
Jeremy Anuntiyo ◽  
Charles J. Malemud ◽  
Tariq M. Haqqi
Keyword(s):  
Rheumatoid Arthritis ◽  
Symptomatic Treatment ◽  
Cartilage Explants ◽  
Unknown Etiology ◽  
Joint Diseases ◽  
History Of ◽  
Inflammatory Drugs ◽  
Anti Inflammatory ◽  
Systemic Nature

Osteoarthritis (OA) of the knee and hip is a debilitating disease affecting more women than men and the risk of developing OA increases precipitously with aging. Rheumatoid arthritis (RA), the most common form of inflammatory joint diseases, is a disease of unknown etiology and affects ∼1% of the population worldwide, and unlike OA, generally involves many joints because of the systemic nature of the disease. Non-steroidal anti-inflammatory drugs (NSAIDs) are the first drugs of choice for the symptomatic treatment of both OA and RA. Because of the risks associated with the use of NSAIDs and other limitations, the use of alternative therapies, such as acupuncture and medicinal herbs, is on the rise and according to reports ∼60–90% of dissatisfied arthritis patients are likely to seek the option of complementary and alternative medicine (CAM). This paper reviews the efficacy of some of the common herbs that have a history of human use and their anti-inflammatory or antiarthritic properties have been evaluated in animal models of inflammatory arthritis, in studies employing well defined and widely acceptedin vitromodels that use human chondrocytes/cartilage explants or in clinical trials. Available data suggests that the extracts of most of these herbs or compounds derived from them may provide a safe and effective adjunctive therapeutic approach for the treatment of OA and RA. This, in turn, argues for trials to establish efficacy and optimum dosage of these compounds for treating human inflammatory and degenerative joint diseases.

scholarly journals Dysmenorrhea and endometriosis in teenage girls (review)

2021 ◽  
Vol 8 (3) ◽  
pp. 133-138
Author(s):  
Ara L. Unanyan ◽  
Laura G. Pivazyan ◽  
Dzhulietta S. Avetisyan ◽  
Archil A. Siordiya ◽  
Anatoliy I. Ishchenko
Keyword(s):  
Symptomatic Treatment ◽  
Reproductive Period ◽  
First Line ◽  
Transabdominal Ultrasonography ◽  
Teenage Girls ◽  
First Line Therapy ◽  
Future Fertility ◽  
Secondary Dysmenorrhea ◽  
Inflammatory Drugs ◽  
Anti Inflammatory

Most adolescents experience discomfort during menstruation. Usually, girls are diagnosed with primary dysmenorrhea in the early reproductive period and respond well to symptomatic treatment with non-steroidal anti-inflammatory or hormonal drugs. If first-line therapy does not improve the symptoms of dysmenorrhea, transabdominal ultrasonography is indicated. Most often, these patients are diagnosed with endometriosis, which is the main cause of secondary dysmenorrhea in adolescents. Endometriosis should be assumed in patients with persistent, clinically pronounced dysmenorrhea that does not respond to treatment with hormonal drugs and non-steroidal anti-inflammatory drugs, especially if no other cause of chronic pelvic pain or secondary dysmenorrhea is detected on the basis of history, physical examination, and ultrasonography of pelvic organs. The aim of the therapy is to relieve symptoms, suppress disease progression, and protect future fertility.

Impact of Medication with Diclofenac Sodium vs. Etoricoxibum in Patients with Inflammatory Reumatic Pathology, Prosthetic Complications and Algo-dysfunctional Syndrome

2017 ◽  
Vol 68 (5) ◽  
pp. 977-981
Author(s):  
Laura Elisabeta Checherita ◽  
Elena Rezus ◽  
Maria Magdalena Leon ◽  
Ovidiu Stamatin ◽  
Elena Mihaela Carausu
Keyword(s):  
Drug Treatment ◽  
Temporomandibular Joint ◽  
Diclofenac Sodium ◽  
Symptomatic Treatment ◽  
Daily Dose ◽  
Before And After ◽  
Inflammatory Drugs ◽  
Anti Inflammatory ◽  
Prosthetic Complications ◽  
Important Objective

Affections of temporomandibular joint (TMJ) can lead to imbalances and disfunctions named algodisfunctional syndrome. One of the affections that we will take into consideration in this study is the temporal-mandibular arthrosis, which is, in fact, the frequent pathology at this level, and to which we will measure the pain before and after the administration of the anti-inflammatory therapy: Etoricoxib vs. Dyclofenac.The important objective of this study is to investigate this type of drug treatment over TMJ. The class of drug called non-steroidal anti-inflammatory drugs (NSAIDs)�so called to distinguish this class of drug from steroids, which have similar but additional effects�make NSAIDs one of frequently used drugs for the symptomatic treatment of many common conditions. Etoricoxib is clinically effective in the therapy of TMJ providing a magnitude of effect comparable to that of the maximum recommended daily dose of Diclofenac.

Adverse Reactions of the Cardiovascular System when Taking Nonsteroidal Anti-inflammatory Drugs and Ways to Reduce Them

2019 ◽  
Vol 15 (5) ◽  
pp. 750-758
Author(s):  
N. V. Pyrikova ◽  
O. N. Antropova ◽  
I. V. Osipova
Keyword(s):  
Cardiovascular Risk ◽  
Cardiovascular System ◽  
Large Scale ◽  
Adverse Reactions ◽  
Symptomatic Treatment ◽  
Pressure Profile ◽  
Total Risk ◽  
Wide Range ◽  
Inflammatory Drugs ◽  
Anti Inflammatory

The most important issue of modern pharmacotherapy is not only efficacy, but also the safety of medicines. The use of nonsteroidal anti-inflammatory drugs (NSAIDs) is one of the main methods of treating acute and chronic pain in a wide range of diseases and pathological conditions. However, the prescription of this group of drugs requires consideration of the potential risks of complications, including from the side of the cardiovascular system. The purpose of the review was to assess the adverse reactions of the cardiovascular system when taking NSAIDs and approaches to their reduction. The article presents data on the mutual potential impact of cardiovascular diseases and musculoskeletal system, presents the results of large-scale studies of Russian and foreign authors and meta-analyzes of the NSAIDs effect on blood pressure profile, development of myocardial infarction, stroke and heart failure. The possible pathogenetic mechanisms of the side effects of NSAIDs are reviewed; the complexity of managing comorbid patients is demonstrated; it is shown that symptomatic treatment of pain and inflammatory syndrome should be carried out considering a personalized approach to the patient and rational choice of drugs.Before the NSAIDs prescription, it is necessary to consider all cardiovascular risk factors with the determination of the total risk of cardiovascular complications. In patients with a very high cardiovascular risk, the use of any NSAIDs should be avoided; with high and moderate risk, the use of NSAIDs with the most favorable cardiovascular safety profile is possible. If the patient belongs to the category of low total coronary risk, the doctor can choose any NSAIDs. 

scholarly journals Role of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) in Cancer Prevention and Cancer Promotion

2019 ◽  
Vol 2019 ◽  
pp. 1-10 ◽  
Author(s):  
Rebecca S. Y. Wong
Keyword(s):  
Side Effects ◽  
Cancer Prevention ◽  
Chronic Inflammation ◽  
Symptomatic Treatment ◽  
Medical Practitioners ◽  
Treatment And Prevention ◽  
Life Threatening ◽  
Inflammatory Drugs ◽  
Anti Inflammatory

The nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly prescribed by medical practitioners in many clinical conditions for the symptomatic treatment of pain and fever. Due to their anti-inflammatory properties, these drugs have been investigated for their anticancer effects in numerous studies. This is because chronic inflammation has long been linked to carcinogenesis. As such, anti-inflammatory drugs are believed to play a role in cancer treatment and prevention. In the past few decades, research has shown that NSAIDs may decrease the risk of certain types of cancer. However, there is also a growing body of research that proves the contrary. Furthermore, NSAIDs are well known for many side effects, including some life-threatening ones. This review will discuss the relationship between chronic inflammation and cancer, the role of NSAIDs in cancer prevention and cancer promotion, and some of the potentially lethal side effects of these drugs.

scholarly journals THU0423 ADHERENCE TO URATE-LOWERING THERAPY IN PATIENTS WITH SEVERE GOUT WHO RECEIVED СANAKINUMAB FOLLOWING A 5-YEAR RETROSPECTIVE ANALYSIS

2020 ◽  
Vol 79 (Suppl 1) ◽  
pp. 449.1-450
Author(s):  
M. Elisеev ◽  
O. Sheliabina
Keyword(s):  
Interleukin 1 ◽  
Symptomatic Treatment ◽  
Symptomatic Therapy ◽  
Lowering Therapy ◽  
Long Term Follow Up ◽  
Inflammatory Drugs ◽  
Acute Attacks ◽  
Anti Inflammatory

Background:The adherence to lowering therapy for gout is low, including in chronic severe gout. Whether interleukin 1 inhibitors may contribute to better adherence is unknown.Objectives:To compare adherence to urate-lowering therapy in patients with severe gout who received canakinumab versus patients who received standard anti-inflammatory therapy (NSAIDs, glucorticoids, colchicine).Methods:Of the 513 patients with gout observed at the V.A. Nasonova Research Institute of Rheumatology, Moscow from 2013 to 2014 y 247 patients with the most severe gout, requiring regular symptomatic treatment, were selected. Of these, 25 patients (3 (12%) women and 22 (88%) men), the average age of 54.5 ± 12.7 g, received (at least 1) canakinumab injection of 150 mg subcutaneously as a symptomatic therapy, the remaining 222 patients (men) mean age 51.9 ± 11.4 g. received standard anti-inflammatory therapy (colchicine (55% of patients), glucorticoids (5%), NSAIDs (40%), or a combination of these (3%). On average, after 4,8 ± 1.7 years, a comparative analysis of adherence to reducing therapy was carried out, as well as the need for anti-inflammatory therapy and assessment of adherence according to the Score compliance on the scale of the Moriscy-Green patients who received and did not receive canakinumab.Results:Evaluation was available in 180 patients (16 who received canakinumab and 164 who received standard anti-inflammatory therapy) who were initially given reducible therapy. 11 patients died (2 patients (8%) who received canakinumab and 9 (4%) patients on standard anti-inflammatory therapy), 56 patients (7 (28%) and 49 (22%), respectively) were not available for observation. Adherence to urate-lowering therapy was better in patients who received canakinumab (see table 1).Table 1.Score compliance on the scale of the Moriscy-GreenAdherence to therapyPatients receiving canakinumab, (n %)Patients receiving standard anti-inflammatory therapy, (n %)р=High (> 4 points)14 (87)83 (51)0,07Moderate (3 points)2 (13)46 (28)0,13Low (2 and <points)035 (21)0,03The likelihood of maintaining the target uric acid level when taking urate-lowering drugs in patients who previously received canakinumab was higher (12 patients (75%) who received canakinumab and 32 (20%) patients received standard anti-inflammatory therapy (p = 0.005).During the year preceding the analysis, there were no acute attacks of arthritis in 12 (75%) patients who received canakinumab and 46 (28%) patients received standard anti-inflammatory therapy (p = 0.002).132 patients who previously received regular anti-inflammatory therapy and received standard anti-inflammatory therapy and 1 patient (1 attack) (p = 0.005) who previously received canakinumab took anti-inflammatory drugs over the past year due to the development of exacerbations (an average of 3 seizures per year): NSAIDs (54%) or colchicine (46%).Conclusion:Therapy with interleukin 1 Kanakinumab may contribute to a better adherence to lowering therapy and isidentified with a lesser need for symptomatic therapy with long-term follow-up.Disclosure of Interests: :Maxim Elisеev Speakers bureau: Novartis, Menarini Group, Alium, Olga Sheliabina: None declared

Polyphenols from Cymbopogon citratus inhibit iNOS expression and NO production – a promising source of new anti-inflammatory drugs

Planta Medica ◽  
2010 ◽  
Vol 76 (12) ◽  
Author(s):  
V Francisco ◽  
A Figueirinha ◽  
B Neves ◽  
C Garcia-Rodriguez ◽  
M Lopes ◽  
...  
Keyword(s):  
Inos Expression ◽  
No Production ◽  
Cymbopogon Citratus ◽  
Inflammatory Drugs ◽  
Anti Inflammatory ◽  
Promising Source
Sign in / Sign up

Export Citation Format

Share Document